Promising use of metformin in treating neurological disorders: biomarker-guided therapies
Neural Regeneration Research · 2024-05 · 19 (5) · 1045-1055
DOI: 10.4103/1673-5374.385286 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neural Regeneration Research, online erschienen am 22.09.2023. Verfasst von Allison Loan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Regenerative Medicine Program, Ottawa Hospital Research Institute; Department of Biology, Faculty of Science, University of Ottawa, Ottawa, ON, Canad…. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 239 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS.
Abstract (Originalsprache)
Neurological disorders are a diverse group of conditions that affect the nervous system and include neurodegenerative diseases (Alzheimer’s disease, multiple sclerosis, Parkinson’s disease, Huntington’s disease), cerebrovascular conditions (stroke), and neurodevelopmental disorders (autism spectrum disorder). Although they affect millions of individuals around the world, only a limited number of effective treatment options are available today. Since most neurological disorders express mitochondria-related metabolic perturbations, metformin, a biguanide type II antidiabetic drug, has attracted a lot of attention to be repurposed to treat neurological disorders by correcting their perturbed energy metabolism. However, controversial research emerges regarding the beneficial/detrimental effects of metformin on these neurological disorders. Given that most neurological disorders have complex etiology in their pathophysiology and are influenced by various risk factors such as aging, lifestyle, genetics, and environment, it is important to identify perturbed molecular functions that can be targeted by metformin in these neurological disorders. These molecules can then be used as biomarkers to stratify subpopulations of patients who show distinct molecular/pathological properties and can respond to metformin treatment, ultimately developing targeted therapy. In this review, we will discuss mitochondria-related metabolic perturbations and impaired molecular pathways in these neurological disorders and how these can be used as biomarkers to guide metformin-responsive treatment for the targeted therapy to treat neurological disorders.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Regenerative Medicine Program, Ottawa Hospital Research Institute; Department of Biology, Faculty of Science, University of Ottawa, Ottawa, ON, Canada.
- Regenerative Medicine Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada.
- Department of Pediatrics and Medicine, Johns Hopkins Medical School, Baltimore, MD, USA.
- Regenerative Medicine Program, Ottawa Hospital Research Institute; Department of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa; University of Ottawa Brain and Mind Research Institute, Ottawa…
Förderung
- NIDDK NIH HHS
Zitieren
APA
Loan, A., Syal, C., Lui, M., He, L., & Wang, J. (2024). Promising use of metformin in treating neurological disorders: biomarker-guided therapies. Neural Regeneration Research, 19(5), 1045-1055. https://doi.org/10.4103/1673-5374.385286
Vancouver
Loan A, Syal C, Lui M, He L, Wang J. Promising use of metformin in treating neurological disorders: biomarker-guided therapies. Neural Regeneration Research. 2024;19(5):1045-1055. doi:10.4103/1673-5374.385286
BibTeX
@article{Loan2024,
author = {Loan, Allison and Syal, Charvi and Lui, Margarita and He, Ling and Wang, Jing},
title = {Promising use of metformin in treating neurological disorders: biomarker-guided therapies},
journal = {Neural Regeneration Research},
year = {2024},
volume = {19},
number = {5},
pages = {1045--1055},
doi = {10.4103/1673-5374.385286}
}
EUVIMED